Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.

@article{Stryjewski2006TelavancinVS,
  title={Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.},
  author={Mart{\'i}n E. Stryjewski and Vivian H. Chu and William D. O'Riordan and Brian L Warren and Lala M Dunbar and David M Young and Marc E Vallee and Vance G. Fowler and Joel Morganroth and Steven L. Barriere and Michael M. Kitt and G. Ralph Corey},
  journal={Antimicrobial agents and chemotherapy},
  year={2006},
  volume={50 3},
  pages={862-7}
}
Telavancin is a bactericidal lipoglycopeptide with a multifunctional mechanism of action. We conducted a randomized, double blind, active-control phase II trial. Patients > or = 18 years of age with complicated skin and skin structure infections caused by suspected or confirmed gram-positive organisms were randomized to receive either telavancin at 10 mg/kg intravenously every 24 h (q24h) or standard therapy (antistaphylococcal penicillin at 2 g q6h or vancomycin at 1 g q12h). A total of 195… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

Similar Papers

Loading similar papers…